Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment.

Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic patient reported outcome (PRO) surveys are collected from the patients using the Carevive platform for a minimum of 12 weeks. Patients may continue weekly surveys as long as they are receiving treatment.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Breast Cancer Acute Myelogenous Leukemia Adnexal Diseases Blood Protein Disorders Breast Diseases Breast Neoplasms Cardiovascular Diseases Endocrine Gland Neoplasms Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Gonadal Disorders Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Immune System Diseases Immunoproliferative Disorders Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Lung Cancer Lung Diseases Lung Neoplasms Lymphoproliferative Disorders Multiple Myeloma Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Plasma Cell Ovarian Cancer Ovarian Diseases Ovarian Neoplasms Paraproteinemias Respiratory Tract Diseases Respiratory Tract Neoplasms Skin Diseases Skin and Connective Tissue Diseases Thoracic Neoplasms Urogenital Diseases Urogenital Neoplasms Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Yale Cancer Center, New Haven, Connecticut, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All participants must be 18 years of age or older.
Subjects may be any stage and anywhere in the treatment continuum.
Subject participants must have a diagnosis of a breast, lung, AML, ovarian cancer or multiple myeloma.
Subjects must be able to complete on-line surveys using a cell phone, tablet, or computer.
All participants must be able to understand English.

Exclusion criteria

Any patient who cannot understand written or spoken English.
Any patient without the ability to complete on-line surveys using a cell phone, tablet, or computer.
Any patient on a treatment clinical trial.
Any prisoner and/or other vulnerable persons as defined by NIH (45 CFR 46, Subpart B, C and D).

Treatment and study plan

Web Based Survey

Other

online weekly survey

Primary outcomes

Create Data Set

Time frame: 1 year

The goal of this registry is to create a data set from real world clinical and patient reported data collected using an electronic care planning system (CPS) that is used in routine care for cancer patients on active treatment

Study contacts

Contact information is provided by the study sponsor or research team.

JULIE SCOTT, MSN

CONTACT

[email protected]

8778423210

Sponsors and collaborators

Lead sponsor

Carevive Systems, Inc.

Industry

Registry information

Official study title

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia (AML) Using Remote Symptom Monitoring

Important dates

Study start: 2023
Primary completion: 2026
Study completion: 2026
First posted: Aug 3, 2023
Registry last updated: Feb 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed